| Drug General Information |
| Drug ID |
D06RRD
|
| Former ID |
DNC000646
|
| Drug Name |
Fibrates
|
| Drug Type |
Small molecular drug
|
| Indication |
Dyslipidaemias [ICD9: 272; ICD10:E78]
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H11ClO3
|
| Canonical SMILES |
CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl
|
| InChI |
1S/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)
|
| InChIKey |
TXCGAZHTZHNUAI-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
67999, 586289, 3138061, 4302949, 8149263, 8151806, 10321140, 10537404, 11112452, 11113721, 11335401, 11360640, 11363054, 11365616, 11368178, 11371371, 11373985, 11376340, 11461612, 11466811, 11467931, 11484030, 11486561, 11487973, 11490172, 11492108, 11493974, 15390199, 24851846, 26528140, 26611666, 26679577, 26747130, 26747131, 26751907, 26751908, 29199188, 29221952, 47291022, 47588878, 47662148, 47736353, 47885292, 47959611, 48034989, 48259105, 48438735, 49698691, 49836655, 50025535
|
| Target and Pathway |
| Target(s) |
Peroxisome proliferator activated receptor alpha |
Target Info |
Agonist |
[1]
|
|---|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
cAMP signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Glucagon signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Hepatitis C
|
|
Pathway Interaction Database
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
Reactome
|
RORA activates gene expression
|
|
BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
PPARA activates gene expression
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Transcriptional activation of mitochondrial biogenesis
|
|
Activation of gene expression by SREBF (SREBP)
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Nuclear Receptor transcription pathway
|
|
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Circadian Clock
|
|
WikiPathways
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
PPAR Alpha Pathway
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
Adipogenesis
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Circadian Clock
|
|
Nuclear Receptors
|
| References |
| REF 1 | Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. |
|---|
